Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported third-quarter 2025 results and detailed a series of regulatory and clinical milestones that could reshape the company’s trajectory as it moves closer …
INOVIO Advances Toward First Commercial Product as BLA Filing Caps Pivotal Quarter Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported third-quarter results that highlight accelerating commercial traction for its lead product, YCANTH®, alongside major regulatory and clinical milestones that broaden …
Verrica Posts Strong Q3 as YCANTH Momentum Builds and Late-Stage Pipeline Advances Read More
WAYNE, PA — BTCS Inc. (Nasdaq: BTCS) reported the strongest quarter in its history, delivering explosive revenue growth and transformative gains tied to its Ethereum-first strategy. The company’s third-quarter results …
BTCS Rockets to Record Revenue as Ethereum Strategy Powers a Breakout Quarter Read More
NORTH WALES, PA — Toppoint Holdings Inc. (NYSE: TOPP) reported third-quarter and nine-month results that show rising momentum across its fastest-growing commodity segments, even as global tariff disruptions weighed on …
Toppoint Posts Strong Revenue Gains as Metal and Import Demand Surges Despite Tariff Pressures Read More
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) reported third-quarter results that reflect a company navigating short-term revenue pressure while securing regulatory and reimbursement wins that could significantly expand …
STRATA Skin Sciences Posts Mixed Q3 as Reimbursement Wins Boost Long-Term Outlook Read More
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) reported continued revenue growth and operational progress in the third quarter of 2025, supported by a strengthened leadership team, expanded sales infrastructure, …
TELA Bio Posts Steady Growth as Strategic Shift Sparks New Commercial Momentum Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported third quarter 2025 financial results and released new analyses showing sustained, long-term therapeutic benefit from its chronic hepatitis B candidate imdusiran …
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) reported third quarter 2025 financial results and highlighted steady momentum across its antiviral programs, including Phase 2 progress for its COVID candidate …
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported third-quarter 2025 financial results and highlighted steady progress across its two clinical-stage DNA damage response (DDR) programs, citing emerging signs of …
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported third-quarter 2025 financial results and detailed a series of clinical, operational, and intellectual-property developments that the company says position its lead …
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise Read More